Bolt Biotherapeutics Inc Dossier
Qualitative Analysis
Business overview
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering a new class of immuno-oncology agents. The company's proprietary Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) platform combines the targeting precision of antibodies with the power of both the innate and adaptive immune systems. By utilizing immunostimulants to engage and activate myeloid cells (such as macrophages and dendritic cells) within the tumor microenvironment, Bolt's candidates aim to directly eliminate tumor cells and induce immunological memory. The company's lead clinical candidate is BDC-4182, a next-generation Boltbody ISAC targeting claudin 18.2, currently in a Phase 1/2 trial for gastric and gastroesophageal cancers.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Concentrating all clinical development resources on BDC-4182, a next-generation Boltbody ISAC targeting claudin 18.2, while implementing step-up dosing protocols to safely reach higher therapeutic doses.
Expected impact: Demonstrate clinical proof-of-concept for the next-generation ISAC platform, which would allow the company to resume development of other pipeline candidates.
Placing the rest of the pipeline on hold, including the Dectin-2 agonist BDC-3042 (which completed Phase 1 dose escalation) and preclinical ISAC programs targeting CEA and PD-L1, while actively seeking development partners.
Expected impact: Conserves capital and extends cash runway while preserving long-term upside through potential licensing or collaboration deals.
Implementation of a major workforce reduction of approximately 50% in late 2025 to significantly lower salary, clinical trial, and general administrative expenses.
Expected impact: Successfully reduced quarterly R&D expenses to $4.8 million and G&A expenses to $2.8 million in Q1 2026, extending the cash runway into 2027.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Collaborating to explore and develop next-generation ISAC programs for cancer treatment using Bolt's proprietary platform technology.
Terms: Ongoing research funding and potential milestone payments; generated portion of historical collaboration revenues.
Combines Bolt's immunostimulatory linker-payloads with Toray's antibodies targeting Caprin-1, a tumor-specific antigen expressed in multiple solid tumor types.
Terms: Ongoing research funding and potential milestone payments.